Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Experimental autoimmune encephalomyelitis (EAE) is a rodent model of multiple sclerosis (MS), a debilitating autoimmune disease of the CNS, for which only limited therapeutic interventions are available. Because MS is mediated in part by autoreactive T cells, particularly Th17 and Th1 cells, in the current study, we tested whether inhibitors of glycogen synthase kinase-3 (GSK3), previously reported to reduce Th17 cell generation, also alter Th1 cell production or alleviate EAE. GSK3 inhibitors were found to impede the production of Th1 cells by reducing STAT1 activation. Molecularly reducing the expression of either of the two GSK3 isoforms demonstrated that Th17 cell production was sensitive to reduced levels of GSK3β and Th1 cell production was inhibited in GSK3α-deficient cells. Administration of the selective GSK3 inhibitors TDZD-8, VP2.51, VP0.7, or L803-mts significantly reduced the clinical symptoms of myelin oligodendrocyte glycoprotein35–55-induced EAE in mice, nearly eliminating the chronic progressive phase, and reduced the number of Th17 and Th1 cells in the spinal cord. Administration of TDZD-8 or L803-mts after the initial disease episode alleviated clinical symptoms in a relapsing-remitting model of proteolipid protein139–151-induced EAE. Furthermore, deletion of GSK3β specifically in T cells was sufficient to alleviate myelin oligodendrocyte glycoprotein35–55-induced EAE. These results demonstrate the isoform-selective effects of GSK3 on T cell generation and the therapeutic effects of GSK3 inhibitors in EAE, as well as showing that GSK3 inhibition in T cells is sufficient to reduce the severity of EAE, suggesting that GSK3 may be a feasible target for developing new therapeutic interventions for MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)
Constantinescu, C. S., Farooqi, N., O'Brien, K., & Gran, B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01302.x · Cited by 1,523
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321 · cited 2×
“Polarization of CD4 T cells toward IFN-g–producing CD4 T cells (Th1 cells) for 5 d was reduced by 66–75% after treatment with lithium, the most widely used GSK3 inhibitor (40, 41), or with the specific GSK3 inhibitor CHIR99021 (42, 43), as determined by flow cytometry after restimulation with PMA/ionomycin (Fig.”
MethodResultSelf-citationRole that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis
McManus, E. J., Sakamoto, K., Armit, L. J., Ronaldson, L., Shpiro, N., Marquez, R., & Alessi, D. R. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600633 · Cited by 594
Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes
Wagman, A., Johnson, K., & Bussiere, D. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043452668 · Cited by 153 · cited 6×
“Polarization of CD4+ T cells toward IFN-g–producing CD4+ T cells (Th1 cells) for 5 d was reduced by 66–75% after treatment with lithium, the most widely used GSK3 inhibitor (40, 41), or with the specific GSK3 inhibitor CHIR99021 (42, 43), as determined by flow cytometry after restimulation with PMA/ionomycin (Fig.”
MethodInfluentialGlycogen synthase kinase-3 is an early determinant in the differentiation of pathogenic Th17 cells
Beurel, E., Yeh, W.-I., Michalek, S. M., Harrington, L. E., & Jope, R. S. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003511 · Cited by 86
Self-citation
Cited by
Glycogen synthase kinase-3 (GSK3): Regulation, actions, and diseases
Beurel, E., Grieco, S. F., & Jope, R. S. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.016 · Cited by 1,768
Self-citationGlycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276
Platt, M. P., Agalliu, D., & Cutforth, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00442 · Cited by 108
Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits
Beurel, E., & Jope, R. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.129 · Cited by 92
Self-citationDiscovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228709 · Cited by 25
Self-citation
Metadata
- Authors
- Beurel, E., Kaidanovich-Beilin, O., Yeh, W.-I., Song, L., Palomo, V., Michalek, S. M., Woodgett, J. R., Harrington, L. E., Eldar-Finkelman, H., Martinez, A., & Jope, R. S.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-05
- Volume
- 190
- Issue
- 10
- Pages
- 5000-5011
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2143395547
- Cited by
- 86
- References
- 5
- FWCI
- 4.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. https://app.cochat.ai/papers/10.4049/jimmunol.1203057
- The paper
- Beurel, E., Kaidanovich-Beilin, O., Yeh, W.-I., Song, L., Palomo, V., Michalek, S. M., Woodgett, J. R., Harrington, L. E., Eldar-Finkelman, H., Martinez, A., & Jope, R. S. (2013). Regulation of Th1 Cells and Experimental Autoimmune Encephalomyelitis by Glycogen Synthase Kinase-3. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1203057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.